Glutamate receptor ligands as anxiolytics

Current Opinion in Investigational Drugs

Volumn 2, Issue 8, 2001, Pages 1112-1119

  Chojnacka Wojcik E ^a   Klodzinska, A ^a   Pilc, A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

AMPA kainate receptor antagonists; Anti anxiety like effects; Anxiety; Competiteve NMDA receptor antagonists; GlycineB receptor partial agonists and antagonists; Group II mGlu receptor agonists; LY 354740; mGlu5 receptor antagonist; MPEP; Non competitive NMDA receptor antagonist

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID ETHYL ESTER; 2 AMINO 5 PHOSPHONOVALERIC ACID; 2 AMINO 7 PHOSPHONOHEPTANOIC ACID; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 (2 CARBOXY 2 PHENYLETHENYL) 4,6 DICHLORO 1H INDOLE 2 CARBOXYLIC ACID; 3 AMINO 1 HYDROXY 2 PYRROLIDINONE; 4 (3 PHOSPHONOPROPYL) 2 PIPERAZINECARBOXYLIC ACID; 6,7 DICHLORO 5 NITRO 2,3 QUINOXALINEDIONE; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; ALPIDEM; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR STIMULATING AGENT; BRETAZENIL; BUSPIRONE; CLOMIPRAMINE; DECAHYDRO 6 [2 (1H TETRAZOL 5 YL)ETHYL] 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; EGLUMETAD; FLUOXETINE; FLUVOXAMINE; GLUTAMATE RECEPTOR; GLUTAMATE RECEPTOR ANTAGONIST; GLYCINE RECEPTOR ANTAGONIST; IMIPRAMINE; MDL 100458; MDL 102288; MRZ 2570; MRZ 2571; MRZ 2576; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEW DRUG; NORADRENALIN UPTAKE INHIBITOR; OXPRENOLOL; PHENCYCLIDINE; PHENELZINE; PROPRANOLOL; SEROTONIN UPTAKE INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANXIETY NEUROSIS; CENTRAL NERVOUS SYSTEM DISEASE; COMPETITIVE INHIBITION; DRUG EFFECT; DRUG PENETRATION; DRUG SYNTHESIS; DRUG TARGETING; HUMAN; NONHUMAN; OBSESSION; REVIEW;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; DISEASE MODELS, ANIMAL; EXCITATORY AMINO ACID AGONISTS; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; RECEPTORS, AMPA; RECEPTORS, GLUTAMATE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 0034876659     PISSN: 09678298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Hypnotics and sedatives
2. Therapeutic activity of alpidem in anxious patients: An overview of European studies
3. Partial benzodiazepine agonists: New concepts in the treatment of panic disorder and schizophrenia
4. Buspirone and diazepam in anxiety: A controlled study
5. Buspirone: A preliminary review of its pharmacological properties and therapeutic efficacy as an anxiolytic
6. Imipramine in the treatment of agoraphobia: Dose-response relationships
7. Antidepressant drugs in anxiety disorders
8. Clomipramine for panic disorder. I. The first 10 weeks of a long-term comparison with imipramine
9. Clomipramine treatment of obsessive-compulsive disorder I. A controlled clinical trial
10. An open trial of fluoxetine in the treatment of panic attacks
11. Fluvoxamine treatment of obsessive-compulsive disorder
12. Phenelzine in social phobia
13. The effect of beta adrenergic blocking drugs on speakers' performance and memory
14. Anxiolytics not acting at the benzodiazepine receptor: Beta blockers
15. The effects of meprobamate, d-amphetamine and promazine on experimentally-induced conflict in rats
16. Effects of behaviorally active drugs in conflict-punishment procedure in rats
17. A simple and reliable conflict procedure for testing anti-anxiety agents
18. Evaluation of a rapid technique for detecting minor tranquilizers
19. Validation of open/closed arm entries in an elevated plus-maze as a measure of anxiety in the rat
20. The use of social interaction as a method for detecting anxiolytic activity of chlordiazepoxide-like drugs
21. The role of the amygdala in fear-potentiated startle: Implications for animal models of anxiety
22. Rat pup ultrasonic isolation calls: Possible mediation by the benzodiazepine receptor complex
23. Glutamate in CNS disorders. A revived target for drug development?
24. Effects of HA 966 on conflict, social interactions and plus maze behaviours
25. Effects of 5,7-dichlorokynurenic acid on conflict, social interaction and plus maze behaviors
26. Amphetamine potentiation of anti-conflict action of chlordiazepoxide
27. Effects of antagonists at the NMDA receptor complex in two models of anxiety
28. Effects of phencyclidine and other N-methyl-D-aspartate antagonists on the schedule-controlled behavior of rats
29. Anxiolytic-like effects of the noncompetitive NMDA antagonist MK 801
30. 1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze
31. Anxiolytic activity of glycine-B antagonists and partial agonists - No relation to intrinsic activity in the patch clamp
32. NMDA receptor complex antagonists have potential anxiolytic effects as measured with separation-induced ultrasonic vocalizations
33. Rat pup isolation calls are reduced by functional antagonists of the NMDA receptor complex
34. N-methyl-D-aspartate antagonists in animal models of anxiety
35. Anticonflict effect of MK-801 in rats: Time course and chronic treatment studies
36. The effects of repeated administration of diazepam, MK-801 and CGP 37849 on rat behavior in two models of anxiety
37. The limbic location of some central effects of competitive and noncompetitive NMDA receptor antagonists: The role in emotional control
38. Selective blockade of N-methyl-D-aspartate (NMDA)-induced convulsions by NMDA antagonists and putative glycine antagonists: Relationship with phencyclidine-like behavioral effects
39. Comparison of competitive and uncompetitive NMDA receptor antagonists with regard to monoaminergic neuronal activity and behavioural effects in rats
40. Anxiolytic actions of competitive N-methyl-D-aspartate receptor antagonists: A comparison with benzodiazepine modulators and dissociative anesthetics
41. Effects of drugs that bind to PCP and sigma receptors on punished responding
42. Effects of phencyclidine-like drugs on punished behavior in rats
43. Antipunishment effects of acute and repeated administration of phencyclidine and NPC 12626 in rats
44. Effects of site-selective NMDA receptor antagonists in an elevated plus-maze model of anxiety in mice
45. Antagonists of the NMDA receptor-channel complex and motor coordination
46. Excitatory amino acids: Implications for psychiatric disorders research
47. Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test
48. 2-Amino-7-phosphonoheptanoic acid (AP7) produces discriminative stimuli and anticonflict effects similar to diazepam
49. Does the excitatory amino acid receptor antagonist 2-APH exhibit anxiolytic activity?
50. Anxiolytic effect in the elevated plus-maze of the NMDA receptor antagonist AP7 microinjected into the dorsal periaqueductal grey
51. Blocking of acquisition but not expression of conditioned fear-potentiated startle by NMDA antagonists in the amygdala
52. The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats
53. Anticonflict effects of a competitive NMDA receptor antagonist and a partial agonist at strychnine-insensitive glycine receptors
54. B receptor partial agonist, D-cycloserine, in rats. Pharmacological analysis
55. Stereoselective R-(+)-enantiomer of HA-966 displays anxiolytic effects in rodents
56. 1-aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models
57. Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnine-insensitive glycine receptors
58. Anxiolytic effect of glycine antagonists microinjected into the dorsal periaqueductal grey
59. Effect of glycine on antidepressant- and anxiolytic-like action of 1-aminocyclo-propanecarboxylic acid (ACPC) in rats
60. Chronic treatment with 1-aminocyclopropanecarboxylic acid desensitizes behavioral responses to compounds acting at the N-methyl-D-aspartate receptor complex
61. B receptors
62. Modulation of NMDA receptors by glycine-introduction to some basic aspects and recent developments
63. Pharmacological characterization of MDL 105,519, an NMDA receptor glycine site antagonist
64. B antagonists as potential therapeutic agents. Previous hopes and present reality
65. MDL 100,458 and MDL 102,288: Two potent and selective glycine receptor antagonists with different functional profiles
66. B antagonists show neuroprotective activity in vivo
67. B receptors
68. Effects of modulation of NMDA neurotransmission on response rate and duration in a conflict procedure in rats
69. Use of a conflict procedure in pigeons to characterize anxiolytic drug activity: Evaluation of N-methyl-D-aspartate antagonists
70. NMDA-coupled periaqueductal gray glycine receptors modulate anxioselective drug effects on plus-maze performance
71. Anxiogenic-like effect of glycine and D-serine microinjected into dorsal periaqueductal gray matter of rats
72. Effects of glycine or (+/-)-3-amino-1-hydroxy-2-pyrrolidone microinjections along the rostrocaudal axis of the dorsal periaqueductal gray matter on rats' performance in the elevated plus-maze task
73. The putative AMPA receptor antagonist, LY326325, produces anxiolytic-like effects without altering locomotor activity in rats
74. Evidence for an anxiogenic action of AMPA receptor antagonists in the plus-maze test
75. Relief of experimental spasticity and anxiolytic/anticonvulsant actions of the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionate antagonist 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(F)quinoxaline
76. Some behavioral effects of AMPA/kainate receptor agonist and antagonists
77. Antagonism of non-NMDA receptors in the dorsal periaqueductal grey induces anxiolytic effect in the elevated plus maze
78. Pharmacology and functions of metabotropic glutamate receptors
79. Anxiolytic-like effects of metabotropic glutamate antagonist (RS)-alpha-methylserine-O-phosphate in rats
80. Agonist analysis of 2-(carboxycyclopropyl)glycine isomers for cloned metabotropic glutamate receptor subtypes expressed in Chinese hamster ovary cells
81. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats
82. Reversible and non-competitive antagonist profile of CPCCOEt at the human type 1 alpha metabotropic glutamate receptor
83. The anti-anxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration
84. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist
85. Discovery of subtype-selective metabotropic glutamate receptor ligands using functional HTS assays
86. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)-pyridine in rodents
87. Potential anxiolytic- and antidepressant-like effects of MPEP, a potent, selective and systemically active mGlu5 receptor antagonist
88. Anxiolytic-like effects of group I metabotropic glutamate antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) in rats
89. Novel allosteric antagonists shed light on mGlu5 receptors and CNS disorders
90. Defense reaction induced by a metabotropic glutamate receptor agonist microinjected into the dorsal periaqueductal gray of rats
91. Sustained behavioral stimulation following selective activation of group I metabotropic glutamate receptors in rat striatum
92. A novel orally active group 2 metabotropic glutamate receptor agonist: LY 354740
93. Synthesis, pharmacological characterization, and molecular modeling of heterobicyclic amino acids related to LY 354740: Identification of LY 379268 and LY 389795: Two new potent, selective, and systemically active agonists for group II metabotropic glutamate receptors
94. Anxiolytic and side-effect profile of LY354740: A potent, highly selective, orally active agonist for group II metabotropic glutamate receptors
95. Design, synthesis, and pharmacological characterization of (+)-2-aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid (LY 354740): A potent, selective, and orally active group 2 metabotropic glutamate receptor agonist possessing anticonvulsant and anxiolytic properties
96. Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models
97. Disinhibitory effects of LY354740, a new mGluR2 agonist, on behaviors suppressed by electric shock in rats and pigeons
98. Stimulation of group II metabotropic glutamate receptors or inhibition of group I ones exerts anxiolytic-like effects in rats
99. LY 354740: A metabotropic glutamate receptor agonist which ameliorates symptoms of nicotine withdrawal in rats
100. LY 354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats
101. Selective agonist of group II glutamate metabotropic receptors, LY 354740, inhibits tolerance to analgesic effects of morphine in mice
102. Pharmacological agents acting at subtypes of metabotropic glutamate receptors
103. Molecular characterization of a new metabotropic glutamate receptor mGluR7 coupled to inhibitory cyclic AMP signal transduction
104. Cloning and characterization of alternative mRNA forms for the rat metabotropic glutamate receptors mGluR7 and mGluR8